Cartherics appoints Dr Ian Nisbet as CEO

28 November 2025

Australian biotech Cartherics has appointed Dr Ian Nisbet as chief executive (CEO) as part of a planned leadership transition. Prof Alan Trounson AO will transition to the role of deputy chairman of the board, where he will continue to provide his expertise to support the company’s strategic direction.

Dr Nisbet is a co-founder of Cartherics and was previously chief operating officer of the company for the past six years. He is an accomplished senior leader in the biotechnology industry, with over 40 years of experience in product development, business development and project management at executive and board levels, in both Australia and the US. Dr Nisbet also serves as a director or advisor to several Australian and US biotechnology companies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK